Ticker brief
IBRX IMMUNITYBIO INC
Consumer, Non-cyclical · Biotechnology
last close
$8.05
1 day
-4.2%
14 days
+6.3%
mkt cap
$9.9B
signals 14d
42
authors 14d
11
crowd 14d
+2.1σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 96% cheap · 13 pctile own 1y | IV/HV 1.56× (as of 2026-07-24) |
| Skew — 25Δ RR 30d | -0.007 15 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +2.23 normal | 5-session Δ -0.68 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-03-25 (z=5.7) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.60 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MisterInversor | C | +0.71 | 9 | +0.48 |
| @PK_Fund | C | +0.11 | 9 | +0.68 |
| @Berlinergy | C | +0.40 | 6 | +0.45 |
| @YYDSxjm | B | -0.51 | 5 | +0.72 |
| @StockChaser_ | C | -2.36 | 3 | +0.42 |
| @kkernttb | C | -2.19 | 2 | +0.48 |
| @SteveDJacobs | C | -1.22 | 2 | +0.15 |
| @SandmanMarkets | C | -2.91 | 2 | +0.58 |
| @StonkValue | C | -1.74 | 2 | +0.40 |
| @jiahanjimliu | A | +0.46 | 1 | +0.35 |
| @dannycheng2022 | C | +1.18 | 1 | +0.00 |
Recent signals30of 42 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @StonkValue | +0.30 | Includes IBRX as a cancer-immunotherapy and commercial-biotech investment play. | — | tweet ↗ |
| 2026-08-28 | @StonkValue | +0.50 | Reports record product revenue and 92% year-over-year growth. | — | tweet ↗ |
| 2026-08-28 | @YYDSxjm | +0.80 | Discloses an existing IBRX holding and a refusal to sell before $100. | — | tweet ↗ |
| 2026-08-28 | @PK_Fund | +0.80 | Enthusiastically promotes ImmunityBio's immune-system thesis and emphasizes ALC as the key metric. | — | tweet ↗ |
| 2026-08-27 | @kkernttb | +0.60 | Identifies a positive range breakout in IBRX. | -4.2% | tweet ↗ |
| 2026-08-27 | @Berlinergy | +0.35 | Highlights IBRX work on a colon-cancer vaccine without a discrete approval or result. | -4.2% | tweet ↗ |
| 2026-08-27 | @PK_Fund | +0.75 | Describes EU packaging completion, distribution progress and expected German revenue this quarter. | -4.2% | tweet ↗ |
| 2026-08-26 | @Berlinergy | +0.40 | ANKTIVA's first EU labeling and packaging is complete and ready for German-speaking markets. | -2.4% | tweet ↗ |
| 2026-08-26 | @SteveDJacobs | +0.20 | Publishes a Thursday stock watchlist based on named technical and momentum-screen badges. | -2.4% | tweet ↗ |
| 2026-08-26 | @PK_Fund | +0.55 | Expresses strong optimism about the potential impact of a lymphopenia designation. | -2.4% | tweet ↗ |
| 2026-08-26 | @YYDSxjm | +0.70 | IBRX should complete a W pattern back to $40. — Expresses a forward bullish chart objective of $40. | -2.4% | tweet ↗ |
| 2026-08-25 | @SandmanMarkets | +0.80 | Enter IBRX at the open, add at 7.64 and 7.10, and stop below 6.57. — Forward IBRX plan specifies an opening entry, two adds and a stop after reclaiming moving averages. | -1.7% | tweet ↗ |
| 2026-08-25 | @SandmanMarkets | +0.35 | Lists five screener-selected stocks for tomorrow's setups, with details in a thread. | -1.7% | tweet ↗ |
| 2026-08-25 | @SteveDJacobs | +0.10 | Publishes a Wednesday stock watchlist based on named technical and momentum screens. | -1.7% | tweet ↗ |
| 2026-08-24 | @Berlinergy | +0.40 | Emphasizes the importance of ANKTIVA's ALC-related implications for IBRX. | +6.2% | tweet ↗ |
| 2026-08-24 | @YYDSxjm | +0.65 | Compiles 17 externally supported regulatory, commercial and pipeline catalysts for IBRX. | +6.2% | tweet ↗ |
| 2026-08-24 | @PK_Fund | +0.80 | Strongly promotes ImmunityBio's T-cell and personalized-therapy prospects. | +6.2% | tweet ↗ |
| 2026-08-23 | @kkernttb | +0.35 | Lists the first six of numerous equities characterized as the best technical setups. | +3.3% | tweet ↗ |
| 2026-08-23 | @StockChaser_ | +0.00 | Promotes forthcoming technical and fundamental recaps for a multi-name watchlist. | +3.3% | tweet ↗ |
| 2026-08-23 | @MisterInversor | +0.40 | Frames longevity and curing disease as a major long-term investment theme. | +3.3% | tweet ↗ |
| 2026-08-22 | @StockChaser_ | +0.55 | Advocates owning five companies whose competitive moats strengthen as they scale. | +3.3% | tweet ↗ |
| 2026-08-22 | @MisterInversor | +0.40 | Highlights five US patents protecting ANKTIVA plus BCG through at least 2035. | +3.3% | tweet ↗ |
| 2026-08-22 | @MisterInversor | +0.50 | Expresses broad decade-long optimism across a basket of technology and healthcare stocks. | +3.3% | tweet ↗ |
| 2026-08-21 | @dannycheng2022 | +0.00 | Maps IBRX's $6.70-$9.60 range and resistance at $10.98 and $12.43. | +3.3% | tweet ↗ |
| 2026-08-20 | @PK_Fund | +0.35 | Reports expected September German authorization and a UK reimbursement assessment for Anktiva. | +2.7% | tweet ↗ |
| 2026-08-20 | @Berlinergy | +0.60 | Highlights older evidence that Anktiva plus Keytruda may prolong survival in lung cancer. | +2.7% | tweet ↗ |
| 2026-08-20 | @Berlinergy | +0.20 | Reports continued hiring at IBRX. | +2.7% | tweet ↗ |
| 2026-08-20 | @StockChaser_ | +0.70 | Argues IBRX's thesis has strengthened through revenue growth, approvals, supply progress, and an FDA catalyst. | +2.7% | tweet ↗ |
| 2026-08-20 | @Berlinergy | +0.75 | Argues Keytruda combination evidence supports Anktiva's broader success. | +2.7% | tweet ↗ |
| 2026-08-20 | @MisterInversor | +0.65 | Forecasts a golden era for human-health investment and associates HIMS and IBRX with the theme. | +2.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.